Deals, R&D

At a cool $1B-plus in upfront, equity and early-stage cash, Regeneron ties a blockbuster R&D partnership knot with RNAi leader Alnylam

Regeneron, the masters of antibody development and cell surface tech, is going inside the cell. And they’ve chosen the RNAi leaders at Alnylam to lead them in — with some very big goals in mind.

The numbers involved in this new, largely preclinical pact are blockbuster proportioned. And that is very rare.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->